期刊文献+

菲立磁增强MRI对局灶性肝病的检出价值及其病理基础

Value of Feridex-enhanced MRI for detection of focal hepatic lesions and analysis of its relevant pathological basis
原文传递
导出
摘要 目的前瞻性评价菲立磁增强扫描对局灶性肝病的检出价值及其病理基础。方法收集经临床、手术病理为诊断金标准证实的26例61个肝局灶性病变,前瞻性对比评价螺旋CT增强扫描、MRI平扫及联合分析MRI平扫+菲立磁增强图像对局灶性肝病的诊断价值。其中20例32个病灶行免疫组化抗CD-68染色,并计数各局灶性病变的Kupffer细胞计数比率。结果螺旋CT增强扫描、MRI平扫及联合分析MRI平扫+菲立磁增强诊断敏感性分别为72%、82%、93%,P<0·05;特异性分别为92%、96%、96%,P>0·05,准确性分别为78%、86%、94%,P<0·05。良性局灶性肝病与恶性病灶包括高分化、中分化、低分化HCC的Kupffer细胞计数比率存在不同,分别为1·54±0·47、0·74±0·30、0·32±0·09、0·28±0·07,差异有显著性(P<0·05)。结论菲立磁增强MRI对肝局灶性病变的检出价值优于螺旋CT增强扫描。局灶性病变与非肿瘤区肝组织内Kupffer细胞含量的差异是菲立磁增强MRI病灶检出的病理基础。 Objective To determine the value of Feridex-enhanced MRI for detection of focal hepatic lesions and analyze its relevant pathological basis. Methods The images obtained by MRI and CT in 26 patients with pathologically and clinically confirmed 61 focal hepatic lesions were prospectively analyzed to compare the detection value among 3 different methods of enhanced helical CT, Feridexenhanced MRI and unenhaneed and Feridex-enhaneed MRI. Thirty-two hepatic lesions in 20 patients were stained by immunohistoehemleal method to calculate the Kupffer-eell-eount ratio of each focal lesion. Results For the enhanced helical CT group, Feridex-enhaneed MRI group and unenhaneed and Feridex-enhaneed MRI group, the diagnostic sensitivity was 72%, 82% and 93% (P〈0.05), specificity 92%, 96% and 96% (P〉0.05) and accuracy 78%, 82% and 93% (P〈0.05), respectively. The Kupffer-cell-count ratio was 1.54±0.47, 0. 74±0. 30, 0. 32±0. 09 and 0. 28±0. 07 for the benign focal hepatic lesions, well-differentiated HCC, moderately differentiated HCC and poorly differentiated HCC, respectively. There was significant difference in the Kupffer-cell-count ratio between the benign focal hepatic lesions and malignant ones (P〈0. 05). Conclusions Feridex-enhanced MRI is superior to enhanced helical CT in detection of focal hepatic lesions. The differences in Kupffer-cellcount ratio and focal lesions are the pathological basis for Feridex-enhanced MRI to detect the lesions.
出处 《中华肝胆外科杂志》 CAS CSCD 2005年第12期793-796,共4页 Chinese Journal of Hepatobiliary Surgery
关键词 肝疾病 磁共振成像 菲立磁 病理 Liver diseases MRI Feridex Pathology
  • 相关文献

参考文献8

  • 1杨汉丰,周翔平,余建群,宋彬,黄娟,李昌宪,李真林,张刚,张青,陈,杨敏.菲立磁增强MRI对局灶性肝病的诊断价值:与螺旋CT对比的ROC曲线分析[J].医学影像学杂志,2004,14(8):671-675. 被引量:2
  • 2周信达.肝癌术后复发的诊断与对策[J].中华肝胆外科杂志,2000,6(3):230-232. 被引量:3
  • 3Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology, 1995, 196:481-488.
  • 4Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology, 1988,168:297-301.
  • 5Hagspiel KD, Neidl KF, Eichenberger AC, et al. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT,intraoperative US, and percutaneous US. Radiology, 1995,196:471-478.
  • 6Raman SS, Lu DS, Chen SC, et al. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. Am J Roentgenol,2001, 177:807-12.
  • 7Seneterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imagign versus unenhanced MR imaging and CT during arterial portograpghy. Radiology, 1996, 200:785-792.
  • 8Kato H, Kanematsu M, Kondo H, et al. Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J Magn Reson Imaging,2004, 19:76-81.

二级参考文献24

  • 1陆才德,彭淑牖,江献川,牟一平.术前肝动脉化疗栓塞对肝细胞癌切除术疗效影响的探讨[J].中华外科杂志,1996,34(7):413-415. 被引量:14
  • 2Vogi TJ, Hammerstingi R, Schwarz W, et al.Superparamagnetic iron oxide-enh anced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions[J].Radiology,1996,198:881-887.
  • 3Ishida T, Murakami T, Kato N, et al. Superparamagnetic iron oxide enhanced magnetic resonance imaging of rat liver with hepatocellular carcinoma and benign hyperplastic nodule[J].Invest Radiol,1997,32:282-287.
  • 4Grandin C,Van Beers B, Robert A, et al. Benign hepatocellul ar tumors: MRI a fter superparamagnetic iron oxide administration[J].J Comput Assist Tomogr,19 95,19:412-418.
  • 5Reimer P, Jahnke N, Fiebich M, et al. Hepatic lesion detecti on and character ization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanc ed MR imaging and spiral CT-ROC analysis[J].Radiology,2000,217:152-158.
  • 6Paley MR, Mergo PJ, Torres GM, et al. Characterization of fo cal hepatic lesi ons with ferumoxides-enhanced T2-weighted MR imaging[J]. AJR, 2000,175:15 9-63.
  • 7Nakayama M, Yamashita Y, Mitsuzaki K, et al. Improved tissue characterizatio n of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging[J]. J Magn Reson Imaging,2000,11:647-654.
  • 8Grangier C, Toumiaire J, Mentha G, et al. Enhancement of li ver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles[J]. J Comput Assist Tomogr,1994,18:888-896.
  • 9Sahani D, Saini S, Sharma R, et al. Dynamic T1-weighted f erumoxides enhan ced MRI for imaging liver hemangiomas: preliminary observations[J]. Abdom Ima ging,2001,26:166-170.
  • 10Ros PR, Freeny PC, Harms SE, et al.Hepatic MR imaging with fer umoxides:a multicenter clinical trial of the safety and efficacy in the detectio n of focal hep atic lesions[J].Radiology, 1995,196:481-488.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部